Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021.

Autor:	Spaander MCW; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., van der Bogt RD; Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Baron TH; Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina, USA., Albers D; Department of Internal Medicine and Gastroenterology, Elisabeth-Krankenhaus Academic Hospital, University of Duisburg-Essen, Essen, Germany., Blero D; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB Erasme Hospital, ULB (Free University of Brussels), Brussels, Belgium., de Ceglie A; Department of Gastroenterology, Ospedale Civile di Sanremo, Sanremo (IM), Italy., Conio M; Department of Gastroenterology, Ospedale Santa Corona, Pietra Ligure (SV), Italy., Czakó L; First Department of Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary., Everett S; Department of Gastroenterology and Hepatology, Leeds Teaching Hospital NHS Trust, Leeds, UK., Garcia-Pagán JC; Barcelona Hepatic Hemodynamic Laboratory, Liver Unit - Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN-Liver) - Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain., Ginès A; Gastroenterology Department, Hospital Clinic of Barcelona, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain., Jovani M; Department of Gastroenterology and Hepatology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA., Repici A; Endoscopy Unit, IRCCS Istituto Clinico Humanitas, Rozzano, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy., Rodrigues-Pinto E; Gastroenterology Department, Centro Hospitalar São João, Porto, Portugal., Siersema PD; Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands., Fuccio L; Gastroenterology Unit, Department of Medical and Surgical Sciences, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy., van Hooft JE; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
Jazyk:	angličtina
Zdroj:	Endoscopy [Endoscopy] 2021 Jul; Vol. 53 (7), pp. 751-762. Date of Electronic Publication: 2021 Apr 30.
DOI:	10.1055/a-1475-0063
Abstrakt:	Malignant Disease: 1: ESGE recommends placement of partially or fully covered self-expandable metal stents (SEMSs) for palliation of malignant dysphagia over laser therapy, photodynamic therapy, and esophageal bypass.Strong recommendation, high quality evidence. 2 : ESGE recommends brachytherapy as a valid alternative, alone or in addition to stenting, in esophageal cancer patients with malignant dysphagia and expected longer life expectancy.Strong recommendation, high quality evidence. 3: ESGE recommends esophageal SEMS placement for sealing malignant tracheoesophageal or bronchoesophageal fistulas. Strong recommendation, low quality evidence. 4 : ESGE does not recommend SEMS placement as a bridge to surgery or before preoperative chemoradiotherapy because it is associated with a high incidence of adverse events. Other options such as feeding tube placement are preferable. Strong recommendation, low quality evidence. Benign Disease: 5: ESGE recommends against the use of SEMSs as first-line therapy for the management of benign esophageal strictures because of the potential for adverse events, the availability of alternative therapies, and their cost. Strong recommendation, low quality evidence. 6: ESGE suggests consideration of temporary placement of self-expandable stents for refractory benign esophageal strictures. Weak recommendation, moderate quality evidence. 7: ESGE suggests that fully covered SEMSs be preferred over partially covered SEMSs for the treatment of refractory benign esophageal strictures because of their very low risk of embedment and ease of removability. Weak recommendation, low quality evidence. 8: ESGE recommends the stent-in-stent technique to remove partially covered SEMSs that are embedded in the esophageal wall. Strong recommendation, low quality evidence. 9: ESGE recommends that temporary stent placement can be considered for the treatment of leaks, fistulas, and perforations. No specific type of stent can be recommended, and the duration of stenting should be individualized. Strong recommendation, low quality of evidence. 10 : ESGE recommends considering placement of a fully covered large-diameter SEMS for the treatment of esophageal variceal bleeding refractory to medical, endoscopic, and/or radiological therapy, or as initial therapy for patients with massive bleeding. Strong recommendation, moderate quality evidence. Competing Interests: T.H. Baron has been a speaker and consultant for Boston Scientific and Cook Endoscopy (2014 to present). A. Repici has been on the advisory board and provided consultancy to Boston Scientific and Medtronic, and provided consultancy to ERBE (all 2017 to present). P.D. Siersema receives research support from Pentax, The eNose company, Norgine, Motus GI, and MicroTech; he is Editor-in-Chief of Endoscopy. M.C.W. Spaander has received research support from Boston Scientific (2013 to present). J.E. van Hooft has provided consultancy to Boston Scientific (2014 to 2017) and Olympus (2021), has received lecture fees from Medtronics (2014, 2015, and 2019) and Cook Medical (2019); her department has received research grants from Cook Medical (2014 to 2019) and Abbott (2014 to 2017). D. Albers, D. Blero, M. Conio, L. Czakó, A. de Ceglie, S. Everett, L. Fuccio, J.-C. Garcia-Pagán, A. Ginès, M. Jovani, E. Rodrigues-Pinto, R.D. van der Bogt declare that they have no conflict of interest. (European Society of Gastrointestinal Endoscopy. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu